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Abstract
Background: Influenza virus infection causes significant morbidity and mortality and has marked
social and economic impacts throughout the world. The influenza surface glycoproteins,
hemagglutinin (HA) and neuraminidase (NA), act cooperatively to support efficient influenza A
virus replication and provide the most important targets for anti-influenza chemotherapy. In this
study, povidone-iodine (PVP-I), which has a broad-spectrum microbicidal property, was examined
for its inhibitory effects against influenza virus infection in MDCK cells and the mechanisms of PVP-
I action on HA and NA were revealed.
Results: Results obtained using a novel fluorescence- and chromogenic-based plaque inhibition
assay showed that 1.56 mg/ml PVP-I inhibited infections in MDCK cells of human (8 strains) and
avian (5 strains) influenza A viruses, including H1N1, H3N2, H5N3 and H9N2, from 23.0–97.5%. A
sialidase inhibition assay revealed that PVP-I inhibited N1, N2 and N3 neuraminidases with IC50
values of 9.5–212.1 μg/ml by a mixed-type inhibition mechanism. Receptor binding inhibition and
hemagglutinin inhibition assays indicated that PVP-I affected viral hemagglutinin rather than host-
specific sialic acid receptors.
Conclusion: Mechanisms of reduction of viral growth in MDCK cells by PVP-I involve blockade of
viral attachment to cellular receptors and inhibition of viral release and spread from infected cells.
Therefore, PVP-I is useful to prevent infection and limit spread of human and avian influenza viruses.
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Background
Among the three types (A, B and C) of influenza viruses,
A type is the most virulent, infecting various avian and
mammalian species and causing human pandemics as a
consequence of antigenic change (antigenic shift) in their
surface glycoproteins, hemagglutinin (HA) and neurami-
nidase (NA) [1]. Sixteen HA and 9 NA subtypes have been
recognized so far [2]. HA and NA interact with sialic acid
receptors on the host cell surface, the former mediating
membrane fusion that results in virus infection and the
latter possessing sialidase activity that cleaves sialyl link-
ages between viral HA and cellular receptors to release
progeny viruses and separate viruses from HA-mediated
self-aggregation, allowing the virus to infect a new host
cell for continuing virus replication [3].
Virus infection can be inhibited by the use of compounds
that bind to viral HA [4-6], inhibit NA activity [7-11] or
inhibit both HA and NA activities [12]. Two NA inhibi-
tors, sialic acid and shikimic acid analogues, have recently
been licensed for treatment of influenza A and B infec-
tions: zanamivir [13] (Relenza®), which is administered
by inhalation, and oseltamivir phosphate [14] (Tamiflu®),
which is administered orally as a prodrug and is converted
by hepatic esterase to its active form, oseltamivir carboxy-
late (OC). However, influenza A and B viruses with muta-
tions in the NA gene have developed resistance to
oseltamivir and zanamivir [15,16]. The worldwide circu-
lation of oseltamivir-resistant seasonal H1N1, highly
pathogenic avian H5N1 [17,18] and the pandemic
(H1N1) 2009 [19] have provided an impetus to develop
new antiviral and antiseptic materials.
In the nineteenth century, povidone-iodine (PVP-I), a
polyvinylpyrrolidone iodine complex, was developed and
found to have a potent broad-spectrum activity against
bacteria, mycobacteria, fungi, viruses and protozoa [20].
PVP-I has become widely used as an antiseptic and disin-
fectant. Despite long-term use, development of PVP-I
resistance in microorganisms has not been reported
[21,22].
PVP-I products have been found to be effective in inacti-
vating a variety of enveloped and nonenveloped viruses,
such as polio [23], herpes simplex, herpes zoster [24], and
human immunodeficiency viruses [25,26]. Anti-influenza
virus activity of PVP-I also has been reported recently [26-
28]. Pretreatment of avian influenza H5N1, H5N3, H7N7
and H9N2 viruses with PVP-I products, such as solution,
scrub, gargle and throat spray, in the range of 0.23–2%,
reduced viral infectious titers to undetectable values in
embryonated hen's eggs [27]. Both aqueous (Betaisod-
ona®) and liposomal PVP-I inactivated human influenza A
virus (H3N2), resulting in reduction of the virus titer by
more than 4 orders of magnitude in Madin-Darby canine
kidney (MDCK) cells [28]. However, the target sites and
mechanisms of PVP-I action on influenza A and the other
virus infections have hitherto remained unknown. In this
study, we investigated mechanisms underlying PVP-I anti-
influenza activity. The apparent reduction of influenza A
viral infectious titers after incubation with PVP-I products
within a short period of time [26-28] led us to investigate
two spike glycoproteins on the viral surface, HA and NA,
which play essential roles in viral infection, as targets of
PVP-I anti-influenza effects.
Results
Inhibition by PVP-I of influenza A virus growth in MDCK 
cells
We first determined the cytotoxicity of PVP-I against
MDCK cells employed as host cells of influenza viruses in
this study by using a cell counting kit-8 assay. Half-maxi-
mum cytotoxic concentration of PVP-I after 24-h exposure
of MDCK cells to PVP-I was 2.4 ± 0.2 mg/ml. PVP-I rang-
ing from 0–1.56 mg/ml, which had no effect on MDCK
cells, reduced virus yield in MDCK cells in a dose-depend-
ent manner (Figure 1B). In comparison with virus yield in
the absence of the inhibitor, 1.56 mg/ml of PVP-I reduced
human virus yield by 59.7–97.5% and avian virus yield by
23.0–57.4%, suggesting enhanced sensitivity towards
human viruses compared to that toward avian viruses.
OC, used as control, inhibited A/Memphis/1/71 (H3N2)
infection by 62% and 73% at concentrations of 0.13 μM
and 80 μM, respectively, whereas it inhibited A/DK/HK/
313/78 (H5N3) infection by 20% and 37%, respectively,
at the same concentrations.
Binding of influenza A viruses to sialoglycopolymers and 
guinea pig erythrocytes and inhibition by PVP-I
In agreement with hemagglutinins from avian and human
influenza viruses, which prefer binding to α2,3- and α2,6-
sialylated polymers, respectively [29], A/Memphis/1/71
and A/DK/HK/313/78 viruses predominately bound to
sialoglycopolymers terminated in α2,6 and α2,3 respec-
tively (Figure 2A). Binding of A/Memphis/1/71 to α2,3
and α2,6 polymers was reduced by fetuin (up to 1.25 mg/
ml) and PVP-I (up to 0.78 mg/ml), whereas that of A/DK/
HK/313/78 was inhibited by fetuin but not by PVP-I (Fig-
ure 2B).
Quantitative inhibition of viral HA binding to sialo-glyco-
conjugate receptors on the erythrocyte surface by fetuin
control and PVP-I is shown in Figure 3A and summarized
for PVP-I activity in Table 1. No erythrocyte hemolysis and
no significant change in pH (pH of each well ranging from
6.52 to 7.20) in the assay system were observed. In gen-
eral, fetuin exhibited higher inhibitory activity (ranging
from 0.02 to 1.25 mg/ml) than that of PVP-I (0.2–12.5
mg/ml).Virology Journal 2009, 6:124 http://www.virologyj.com/content/6/1/124
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A qualitative analysis of hemagglutination inhibition
showed that hemagglutination (guinea pig erythrocyte
clumping) of human A/Memphis/1/71 (~400 hemagglu-
tination units (HAU)) and avian A/DK/HK/313/78 (~400
HAU) was completely inhibited by 2.50 mg/ml and 5.00
mg/ml of PVP-I, respectively (Figure 3B).
Effect of PVP-I on influenza A virus sialidase activity
In order to examine the effect of PVP-I on sialidase activity
of different subtypes of influenza virus strains, the enzyme
activity and Km value of each virus subtype were deter-
mined at pH 6.0 using 2'-(4-methylumbelliferyl)-α-D-N-
acetylneuraminic acid (MUNA), a sensitive fluorogenic
substrate without 2,3 and 2,6 linkages. Then an inhibition
assay was performed using 2 enzyme units of each virus
subtype and substrate concentration at its Km value. IC50
values of OC against sialidase of different virus strains
were ranged from 0.37 to 6.88 nM (data not shown).
There were marked differences in IC50 values for PVP-I,
from 9.5 to 212.1 μg/ml depending on the virus strain
(Table 1).
The kinetic mechanism by which PVP-I inhibits influenza
A virus sialidase activity was investigated by determining
kinetic parameters of human A/PR/8/34 (H1N1) sialidase
on hydrolysis of MUNA in the absence and presence of an
inhibitor. As shown in Table 2, with OC or 2-deoxy-2,3-
dehydro-N-acetylneuraminic acid (DANA), Km  values
increased, but Vmax did not change. In the presence of PVP-
I, Km values increased and Vmax decreased. Vmax/Km ratio
decreased 6-fold, 6-fold and 12-fold in the presence of 4
nM OC, 75 μg/ml PVP-I and 5 μM DANA, respectively,
indicating decrease in sialidase efficiency. Lineweaver-
Burk plots showed that inhibition of A/PR/8/34 sialidase
activity by OC and DANA was of a competitive type,
whereas that by PVP-I was of a mixed type (Figure 4). The
Inhibitory effect of PVP-I on influenza viral infection in MDCK cells Figure 1
Inhibitory effect of PVP-I on influenza viral infection in MDCK cells. (A) A simplified diagram of the infection assay 
used in this study. (B) Quantification of viruses in cells at Ex355/Em460 is expressed as percent virus yield (left Y axis) and per-
cent inhibition (right Y axis) of untreated infected cells.
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Ki values for free sialidase for OC, DANA and PVP-I were
0.66 nM, 432.60 nM and 11.74 μg/ml, respectively, and
the Ki for sialidase-MUNA complex for PVP-I was 190.63
μg/ml, whereas Km for MUNA was 14.66 μM (7.17 μg/
ml). Thus, the competitive inhibitors OC and DANA
exhibited 2.21 × 104- and 34-fold higher affinities for
influenza sialidase, respectively, than that of MUNA,
whereas the mixed-type inhibitor PVP-I, with two inhibi-
tion constants, Ki for free sialidase and Kis for bound siali-
dase complex, had 1.6- and 26.6-fold lower affinities than
that of MUNA, respectively.
Discussion
Iodine is a nonmetallic essential nutrient with a potent
broad range of microbicide actions against almost all of
the important health-related microorganisms, including
bacteria, fungi, viruses and protozoa. Although a high
content of iodine species with free molecular form (I2)
and hypoiodous acid (HOI) in aqueous solution has pow-
erful microbicidal effects but can cause volatility, stinging
and cytotoxicity [30-32]. To overcome these problems,
iodine was combined with neutral carrier polymers to
increase iodine solubility and to keep low the release of
iodine as a solubilizing agent and to act as an iodine res-
ervoir [30,33]. The most popular carrier in current use is
povidone [32,33], which has no microbicidal activity
[34]. Since povidone slowly and continuously releases
free iodine into solution, these properties help to main-
tain antimicrobial capacity for a long period and to
decrease toxicity.
By using the cell counting kit-8 assay, we found that the
IC50 cytotoxicity of MDCK cells following 24-h exposure
to PVP-I was 2.4 ± 0.2 mg/ml. Based on morphological
Effect of PVP-I on direct binding activity of influenza viruses to glycopolymers Figure 2
Effect of PVP-I on direct binding activity of influenza viruses to glycopolymers. (A) Virus binding activity to glyco-
polymers linked with α2,3 (filled red square) and α2,6 (filled blue triangle)-sialic acids. (B) Inhibition of virus binding to a specific 
polymer. Percentage of untreated control viruses was plotted against inhibitor concentration. (filled green square) α2,3 linkage 
+ PVP-I; (empty pink square) α2,3 linkage + fetuin; (filled green triangle) α2,6 linkage + PVP-I; (empty pink triangle) α2,6 linkage 
+ fetuin.
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criteria [35], cell shrinkage, rounding and detachment
from the surface of the culture plate after treatment with
3.1 mg/ml of PVP-I suggested that the cells were undergo-
ing apoptosis. Therefore, we used low concentrations of
PVP-I that did not cause any toxicity to host MDCK cells
in order to investigate its anti-influenza virus activity.
Our results confirmed that PVP-I is a potent inhibitor of
influenza virus production in MDCK cells. We indicated
that PVP-I inhibits the viral replication in a dose depend-
ent manner and is more active against human viruses
(H1N1, H3N2) than avian viruses (H1N1, H5N3, H9N2).
PVP-I appeared to inhibit binding of human A/Memphis/
1/71 (H3N2) virus to specific sialoglycopolymers but not
that of avian A/DK/HK/313/78 (H5N3) virus. Hemagglu-
tination of erythrocytes induced by human viruses was
inhibited by PVP-I, while hemagglutination inhibition of
avian viruses required higher PVP-I concentrations. Dif-
ferences in hemagglutination inhibitory activity of PVP-I
against various viruses may be associated with the differ-
ent structure of HA protein of each virus type. Unlike the
α2,3 and α2,6 sialoconjugated protein fetuin [36], which
reduces HA binding activity of both avian and human
influenza viruses via competition for binding with sialylo-
ligosaccharide receptor substrates to the viruses [37],
blockage of viral HA attachment to receptor substrates by
PVP-I may result from alteration of viral HA protein struc-
ture by reaction of free iodine with basic -NH groups, phe-
nolic groups, and -SH groups of amino acid residues [30].
Although avian viruses appear to be less sensitive than
human viruses to PVP-I, based on results of the erythro-
cyte agglutination assay, which reflects viral attachment to
host cells, agglutination of avian A/DK/HK/313/78 virus
(~400 HAU) was completely inhibited after a second
exposure to 5 mg/ml of PVP-I. This is in agreement with
the finding that titers of a highly pathogenic avian virus
(H5N1) and three low pathogenic avian viruses (H5N3,
H7N7 and H9N2) cultivated in embryonated eggs
become undetectable by incubation with a commercial
PVP-I product for 10 seconds before inoculation [27].
These results suggest that gargling with PVP-I could pre-
vent human infection not only by human influenza
viruses that bind to sialyl α2,6 Gal receptors in the upper
part of human trachea but also by avian viruses that bind
to sialyl α2,3 Gal receptors that exist deep in the human
respiratory tract [38]. This could consequently minimize
the risk of avian virus mutation, either by adaptation or
reassortment, to recognize the human host predominately
carrying α2,6-linked sialic acids.
PVP-I inhibited sialidase activity as a mixed-type inhibi-
tor, indicating that free iodine is capable of binding to
either free sialidase or sialidase complexed with its sub-
strate, but iodine binding to free sialidase is more efficient
than that to sialidase-substrate complex as Ki was 16-fold
lower than Kis. This may be explained by the distribution
of lysine, arginine, histidine, cysteine and tyrosine resi-
dues throughout the sequence of the NA molecule, which
Table 1: Inhibition by PVP-I of sialidase activity, hemagglutination and infectivity activity of influenza A viruses
Virus subtype Virus strain Sialidase inhibition activity
IC50
a (μg/ml)
Hemagglutination inhibition
activityb (mg/ml)
Infection inhibitory activity (%)c
H1N1 A/Bel/42 11 ± 2 1.56 84 ± 1
A/Texas/36/91 72 ± 4 0.78 68 ± 3
A/USSR/92/77 47 ± 3 0.78 68 ± 2
A/PR/8/34 9.5 ± 0.5 0.20 62 ± 2
A/WS/33 12.5 ± 0.5 0.78 60 ± 4
A/WSN/33 45 ± 1 0.39 97 ± 1
A/DK/HK/36/4 21 ± 5 12.50 40 ± 4
H3N2 A/Aichi/2/68 96 ± 2 3.13 82 ± 5
A/Memphis/1/71 61 ± 4 1.56 66 ± 3
H9N2 A/DK/HK/92/76 212 ± 9 12.50 34 ± 8
H5N3 A/DK/HK/313/78 78 ± 4 12.50 23 ± 1
A/DK/HK/23/76 124 ± 7 3.13 57 ± 4
A/DK/HK/677/1 55 ± 1 3.13 50 ± 3
aIC50values are concentrations inhibiting viral sialidase activity by 50%. Standard error means were calculated from means of two independent 
experiments, each conducted in duplicate.
bMinimum concentration that inhibits hemagglutination.
cPercent viral inhibition (with 1.56 mg/ml of PVP-I) was calculated by comparison with the control without an inhibitor. Each experiment was 
performed in triplicate.Virology Journal 2009, 6:124 http://www.virologyj.com/content/6/1/124
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are reactive with iodine [30]. Although the Ki value for
iodine was higher than the Km value, indicating that affin-
ity of the MUNA substrate for sialidase is higher than
iodine, the activity of sialidase to hydrolyze MUNA (Vmax/
Km = 0.12) was reduced in the presence of PVP-I (75 μg/
ml) (Vmax/Km = 0.02), comparable to that in the presence
of OC (4 nM). The reduction in sialidase activity should
result in a decrease in influenza replication.
There have been a number studies on the development of
harmless carriers (such as cyclodextrin) that slowly release
free iodine at a concentration retaining antimicrobial
activity without a cytotoxic effect against mammalian cells
for use of iodine in therapeutic applications [28,39].
Intravenous administration of iodine-lithium-α-dextrin
has successfully prevented lethal infection of Staphylococ-
cus aureus in rats [39].
Conclusion
Our study confirms the inhibition of avian and human
influenza A virus infection by PVP-I and demonstrates
that PVP-I inhibits both viral HA binding activity and viral
NA catalytic hydrolysis, mediating virus entry into host
cells, and virion release and spread to a new host cell,
respectively. Thus, PVP-I, for which there has been no
report of resistance, is a potential agent that not only pre-
vents viral infections but also reduces the spread of influ-
enza viruses in epidemic and pandemic areas.
Methods
Viruses and cells
Viruses were propagated in 10-day-old embryonated
chicken eggs at 34°C, and after 48 h of incubation, allan-
toic fluid was harvested, cleared and concentrated. The
virus pellet was resuspended in cold phosphate-buffered
Inhibition by PVP-I of influenza virus hemadsorption activity on guinea pig erythrocytes Figure 3
Inhibition by PVP-I of influenza virus hemadsorption activity on guinea pig erythrocytes. (A) Quantification of 
minimum fetuin (left panel) or PVP-I (right panel) concentration required for inhibition of virus erythrocyte agglutination. (B) 
Visualization of virus erythrocyte agglutination under a light microscope. Bars = 50 μm. Agglutination morphology was com-
pared with positive (no PVP-I) and negative (no virus) controls.
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saline (PBS), divided into aliquots, and kept at -80°C
until use. Virus titers expressed as HAU were determined
(see below) before experimentation. Protein concentra-
tion was determined by using a BCA™ protein assay kit
(Pierce, Rockford, IL, USA) with bovine serum albumin
(BSA) as a standard. MDCK cells were cultured in Eagle's
minimal essential medium (EMEM) supplemented with
5% fetal calf serum, antibiotics (penicillin-streptomycin)
and glutamine at 37°C in an atmosphere of 5% CO2.
Monoclonal antibodies
Monoclonal antibody 4E6 (mouse IgG1 subtype) directed
to influenza virus nucleoprotein (NP) was obtained using
A/Memphis/1/71 (H3N2) as an antigen. Monoclonal
antibody 2E10 (mouse IgG1 subtype) directed to H3 HA
and 2G3 (IgG1) directed to H5 HA was prepared using
reassortant virus A/Memphis/1/71 (H3)-A/Bellamy/42
(N1) and A/duck/HK/313/4/78 (H5N3) as an antigen,
respectively [40].
Cytotoxicity assay (Cell counting kit-8 assay)
Toxicity of PVP-I (Meiji Seika Kaisha, Tokyo, Japan)
against MDCK cells was examined using a cell counting
kit-8 (DOJINDO Laboratories, Kumamoto, Japan) to
determine the numbers of viable cells using WST-8 [2-(2-
methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disul-
fophenyl)-2H-tetrazolium, monosodium salt] as a sub-
strate. In brief, confluent monolayers of MDCK cells in a
96-well plate were washed with serum-free EMEM and
incubated with PVP-I at a final concentration ranging
from 0–25 mg/ml for 24 h at 37°C in 5% CO2 atmos-
phere. After removal of PVP-I solution, cell viability was
determined by addition of kit reagent, incubation for 1 h
at 37°C, and measurement of absorbance at 450 nm.
PVP-I concentrations showing no cytotoxicity against
MDCK cells were used in viral infection assay.
Viral infection inhibition assay
Inhibitory effects on virus development in MDCK cells
were determined as shown in Figure 1A. An aliquot of
virus (V) at the optimal dose (input virus causing 5 × 105
fluorescent forming units, which corresponds to 250 PFU/
well equivalent to a multiplicity of infection (MOI) of
0.025 PFU/cell, in the absence of an inhibitor [41]) was
preincubated with an equal volume of serial dilutions of
an inhibitor (I) or serum-free EMEM (100% infection) at
4°C for 1 h (Pretreatment step). A 100-μl aliquot of virus-
inhibitor mixture (V+I) was overlaid on MDCK cells in
96-well plates at 34°C for 1 h (Viral adsorption step).
After washing with serum-free EMEM, virus-infected cells
were cultured in serum-free EMEM containing 2.5 μg/ml
acetylated trypsin with or without the inhibitor (at the
same concentration as that in preincubation) for 18–19 h
at 34°C (Treatment step). Then the cell monolayer was
washed with PBS, fixed with methanol for 1 min, and
incubated with anti-nucleoprotein mouse IgG (4E6) for
45 min at room temperature. β-galactosidase-labeled anti-
mouse IgG with 0.1% block-ace was added and incubated
for 45 min at room temperature. Then the enzyme reac-
tion was started by adding 40 μM 4-methylumbelliferyl-β-
D-galactoside (MU-Gal) with 50 μM MgCl2. After 45 min
of incubation at 37°C, the reaction was stopped by addi-
tion of 100 mM sodium carbonate buffer (pH 10.6). Flu-
orescent intensity of released 4-methylumbelliferone
(MU) was measured by excitation at 336 nm and emis-
sion at 490 nm (Ex355/Em460) using a fluorescence
microplate reader (Fluorescence staining step).
Hemagglutination and hemagglutination inhibition assays
For virus quantitation, a 5-μl aliquot of virus sample seri-
ally diluted in PBS was incubated with 50 μl of 0.5% sus-
pension of guinea pig erythrocytes for 2 h at 4°C. Virus
Table 2: Effects of inhibitors on kinetics parameters of A/PR/8/34 (H1N1) sialidase activity
Kinetic parameter No inhibitor OC
(4 nM)
PVP-I
(75 μg/ml)
DANA
(5 μM)
Vmax(μmol/l.min) 1.70 1.68 1.22 1.69
Km (μmol/l) 14.66 103.20 77.72 184.10
Km (μg/ml)a 7.17 - - -
Vmax/Km(1/min) 0.12 0.02 0.02 0.01
Type of inhibition - Competitive Mixed Competitive
Ki(nM) - 0.66 - 432.60
Ki (μg/ml) - - 11.74 -
Kis (μg/ml) - - 190.63 -
Km/Ki -2 . 2 1  ×  1 0 4 0.61 33.90
Km/Kis -- 0 . 0 4-
aMW of MUNA is 489.39.Virology Journal 2009, 6:124 http://www.virologyj.com/content/6/1/124
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titers expressed as HAU were determined by visual read-
ing.
For determination of inhibition of HA binding, a 25-μl
aliquot of fetuin or PVP-I serially diluted in PBS was pre-
incubated with 25 μl of virus (4 HAU) in 96-well U-bot-
tom plates at 4°C for 1 h. Hemagglutination was
determined as described above.
To visualize agglutination directly, 100 mg/ml of PVP-I
was added to a well of a 24-well flat-bottom plate to give
a final concentration of 1.25, 2.50, 3.75 or 5.00 mg/ml,
followed by addition of 5 μl of virus (214 HAU) to obtain
a final HAU of about 400 [42]. To avoid possible cleavage
of virus-erythrocyte binding by sialidase, erythrocyte
agglutination was observed under a light microscope
immediately after addition of 200 μl of 0.25% erythrocyte
suspension.
Receptor binding inhibition assay
Specific binding of virus to α2,3 and α2,6 sialoglycopoly-
mers was performed in 96-well plates coated with 0–
2,000 ng/ml of sialoglycopolymers as described previ-
ously [43]. Briefly, after blocking the plates with 1%
block-ace in PBS, viruses (64 HAU) in PBS containing
0.1% Tween 20 (PBST) were added and incubated for 2 h
at 4°C. Viruses bound to sialoglycopolymers were
detected by anti-HA mouse IgG and HRP-conjugated goat
anti-mouse IgG+M, each step being conducted at 4°C for
2 h and followed by washing with PBST 5 times. The reac-
tion color was developed by adding o-phenylenediamine
(OPD) and H2O2 in 100 mM citrate buffer (pH 6.0), pre-
pared according to the instruction manual (Wako, Osaka,
Japan), terminated by adding H2SO4, and assessed by
measuring optical densities at 492 and 620 nm.
A receptor inhibition experiment was performed as
described above, but each virus (12 HAU) was preincu-
bated with PVP-I (0–780 μg/ml) or fetuin (0–1,250 μg/
ml) in PBST at 4°C for 2 h before the virus mixture was
added to the plate coated with 50 ng/ml of sialoglycopol-
ymer.
Sialidase inhibition assay
Five μl of 2 viral enzyme units (one unit being the amount
required to liberate 1 nmole of product per min) was pre-
incubated with 5 μl of an inhibitor serially diluted in 20
mM sodium acetate buffer (pH 6.0) at 37°C for 15 min.
Enzymatic reaction was started by addition of 5 μl of
MUNA to a final concentration equivalent to a Km value of
Lineweaver-Burk plots of inhibition of A/PR/8/34 (H1N1) sialidase activity by OC, DANA and PVP-I Figure 4
Lineweaver-Burk plots of inhibition of A/PR/8/34 (H1N1) sialidase activity by OC, DANA and PVP-I. (empty blue 
diamond) no inhibitor; (filled pink circle) 4 × 10-9 M OC; (filled green triangle) 75 μg/ml PVP-I; (empty orange upside down tri-
angle) 5 × 10-6 M DANA.
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each virus. After 15 min at 37°C, the reaction was termi-
nated by adding 200 μl of 100 mM sodium carbonate
buffer (pH 10.6). The released MU products were meas-
ured at Ex355/Em460.
To determine the inhibition mechanism, 5 μl of 2 viral
enzyme units was incubated with 5 μl of 280–1000 μM
MUNA either alone or in the presence of 5 μl of OC,
DANA or PVP-I for 15 min at 37°C. The MU products
were measured as described above. Data were fitted to the
Michaelis-Menten equation for determination of appar-
ent Vmax and Km values and then transformed and plot-
ted as Lineweaver-Burk plots using GraphPad Prism
software. Inhibition constant of each inhibitor was calcu-
lated according to their inhibition type as follows:
For competitive inhibitor, Kmapperance = Km(1+I/Ki).
For mixed-type inhibitor, Vmaxapperance = Vmax/(1+(I/Kis))
and Kmapperance = Km(1+I/Ki)/(1+I/Kis).
Ki  and Kis  are dissociation constants for free enzyme-
inhibitor and substrate-bound enzyme-inhibitor com-
plex, respectively.
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